Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Intergroupe Francophone de Cancerologie Thoracique
With
Bristol-Myers Squibb
Although the oncogene addiction concept has led to effective targeted treatments for certain histological non-small cell lung cancer (NSCLC) types, most patients with advanced tumors are still treated with first-line chemotherapy. In 2015, several studiess demonstrated the efficacy of nivolumab, an immunotherapy targeting immune checkpoints. In France, besides the clinical trials, this molecule has been made available in January 2015 under a Temporary Authorization for Use (ATU, compassionate use).
Our study sought to examine nivolumab efficacy and safety in advanced NSCLC patients treated under the ATU setting and describe their long-term clinical characteristics, notably the treatments they received after nivolumab discontinuation. The profile of these patients shows greater conformity to that of a non-selected population, yet the clinical data collection does not reflect "real life" conditions and stops when treatment ends, which does not enable us to get an overview of post-immunotherapy treatments.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
All patients with advanced NSCLC, non-eligible for thoracic radiation therapy, having received nivolumab (at least one injection), under nominative or cohort ATU, between 23-JAN-2015 and 31-AUG-2015 (end of ATU).
You may not be if
patients included in a biomedical research trial with nivolumab
patients \<18 years old
patients included under ATU to receive nivolumab administration, but never did
patients with a psychiatric history that hinders the comprehension of the information leaflet